

## Correction

# **Correction: Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin**

Graham A Colditz

Alvin J Siteman Cancer Center and Department of Surgery, Washington University School of Medicine, Campus Box 8100 660 S Euclid Avenue, St Louis, MO 63110, USA

Corresponding author: Graham A Colditz, [colditzg@wustl.edu](mailto:colditzg@wustl.edu)

Published: 15 November 2007

*Breast Cancer Research* 2007, **9**:401 (doi:10.1186/bcr1786)

This article is online at <http://breast-cancer-research.com/content/9/6/401>

© 2007 BioMed Central Ltd

Due to an oversight, the author of the above article [1] was incorrectly listed as having no competing interests. The competing interests section of this article should have read:

### **Competing interests**

GC has served as an expert witness for plaintiff lawyers preparing hormone therapy litigation. GC has received research support from GlaxoSmithKline, from the American Cancer Society, and from the Breast Cancer Research Foundation. No group or organization funded this manuscript.

### **Reference**

1. Colditz GA: **Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin.** *Breast Cancer Research* 2007, **9**:108.